BioNTech and Pfizer will start a clinical trial of a Covid-19 vaccine adapted to the BA.4 and BA.5 variants of Omicron this month, as the German biotech forecasts an increase in demand at the end of the year.
BioNTech和輝瑞(Pfizer)一款針對Omicron BA.4和BA.5亞型變體毒株的新冠疫苗將在本月投入臨床試驗。BioNTech預計年底需求將會增加。
您已閱讀6%（289字），剩余94%（4305字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。